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Dual chamber pacemaker/defibrillators combine pacemaker
and implantable defibrillator technology. Despite the lack of
randomized or prospectively collected data to support this
practice, 66% of implantable cardiovertor defibrillators
(ICDs) implanted in the USA, during the 12 months ending
April 30 2001, were dual chamber devices [C Gennaro,
personal communication]. The additional cost to the system
for the dual chamber ICDs ranges from US$2500 to
US$5175 per patient.
The results of multicenter, randomized clinical trials of atrial or
dual chamber pacemakers compared to ventricular
pacemakers have been particularly sobering [1–3]. These
trials suggest that there is a role for dual chamber
pacemakers, but their impact is not nearly as dramatic as
would be expected from the groundswell of support from
experts in the field and its common usage particularly in
Europe and in the USA. Are there reasons to believe that the
addition of the atrial lead, rate responsive sensor, and dual
chamber pacing modes, will help patients more than a single
chamber ventricular pacemaker (VVI)/ICD? Perhaps there are,
but with the modest improvements observed in the
pacemaker realm, it is incumbent on the electrophysiology
community to measure the incremental benefit of the dual
chamber rate-adaptive pacemaker (DDDR)/ICDs. The DAVID
(Dual Chamber and VVI Implantable Defibrillator) trial is
designed to measure this benefit.
DAVID trial protocol design
The DAVID trial is a US, multicenter, randomized comparison
of dual chamber rate responsive pacemaker ICD therapy to
ventricular pacing ICD therapy. It is administered by the
Department of Biostatistics, University of Washington, WA,
and is funded by a research grant from St Jude Medical
(Sylmar, CA). The inclusion criteria require that the patients
have a left ventricular ejection fraction (LVEF) of 40% or less,
and one of the following conditions:
1. Survived a ventricular fibrillation (VF) arrest.
2. Documented spontaneous ventricular tachycardia (VT)
with, or without, syncope.
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Abstract
All of the prospective multicenter trials that support the use of implantable defibrillators have used
single chamber pacemakers/implantable cardiovertor defibrillators (ICDs). Despite the significantly
increased cost of dual chamber pacemaker/ICD devices and the lack of outcome data, these devices
accounted for approximately two-thirds of the ICDs implanted in the United States during the
12 months ending April 2001. Dual chamber pacemaker trials have not provided data that would
support this trend, but the high incidence of atrial fibrillation, bradycardia, and congestive heart failure,
as comorbid conditions, suggest that the situation could be different in the defibrillator patient
population. The DAVID (Dual Chamber and VVI Implantable Defibrillator) trial is designed to measure
the incremental benefit of dual chamber pacemaker/ICDs.
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3. Electrophysiology study (EPS)-induced VT and a history
of syncope.
4. Spontaneous, non-sustained VT, with sustained
monomorphic VT induced during EPS.
Patients are excluded if they:
1. Have reversible causes of the VT/VF event.
2. Have permanent pacemakers.
3. Have seconddegree, third degree, or advanced,
atrioventricular block.
4. Have symptomatic bradycardia.
5. Have pre-existing endocardial pacing leads.
6. Have permanent atrial fibrillation.
7. Are waiting for a cardiac transplantation.
8. Have a life expectancy of less than 1 year.
Eligible patients must have an indication for ICD therapy
but have no indication for pacemaker therapy. All patients,
however, receive a DDDR/ICD system, and the device is
randomly programmed either to VVI pacing or to DDDR
pacing. Although the patients randomly allotted to the VVI
arm of the study have the atrial lead electrogram recording
activated, the atrial signal is not used to aid in the
diagnosis of arrhythmias. The investigators hypothesized
that the atrial lead and the associated pacing modes and
diagnostic capabilities in the DDDR mode will improve
prognosis, quality of life and cost of care for patients with
defibrillators.
All patients are treated aggressively for associated
cardiovascular comorbidities. The primary endpoint is either
mortality or hospitalization for congestive heart failure. Data
from the AVID (Antiarrhythmics Vs Implantable Defibrillators)
trial demonstrated that in a very similar patient population
there was a 50% mortality rate within 2 years after a
hospitalization for congestive heart failure. The primary
comorbidity that affects mortality is congestive heart failure,
so only patients with LVEF of 40% or less are included, and
all patients are to be treated with beta-blockers, angiotensin-
converting-enzyme inhibitors and other appropriate heart
failure therapies.
Contrasting pacemaker and ICD patients
The patients treated with pacemakers are quite different to
those treated with ICDs. Overall, the ICD population is sicker
than the pacemaker population [4–7]. In every ICD study, the
average LVEF, ventricular size, New York Heart Association
Functional Class and quality of life scores are worse. In
addition, the prevalence of congestive heart failure is lower in
the pacemaker outcome studies than in the ICD outcome
studies. Possibly the healthier nature of the patients in the
pacemaker outcome trials is responsible for the benefit of the
dual chamber mode becoming manifest only after prolonged
follow up. If this is true, then patients with more advanced
cardiac dysfunction, such as ICD patients, are more likely to
demonstrate the benefit of dual chamber pacing.
In addition, there are significant differences in the
programming and pacing therapy that is given to pacemaker
patients and ICD patients. Pacemaker outcome studies
compare patients programmed to the VVI(R) (VVI with rate
response) or DDD(R) (dual chamber pacemaker with rate
response) mode with the base rate and rate response
designed to provide pacing for a significant portion of each
day. Patients in most ICD outcome studies, however, were
specifically screened to exclude the need for bradycardia
support. In these studies, the ICD was programmed to the
VVI mode, usually at the rate of 30–40 bpm, in an attempt to
avoid pacing except during episodes of severe bradycardia.
Use of VVI/ICDs to increase heart rate was considered ill
advised because it often caused sensing problems due to
interactions with the autogain algorithms and accelerated
battery depletion, and it had the potential to produce
pacemaker syndrome. Therefore the comparison of VVI/ICDs
to DDDR/ICDs is, in fact, the comparison of intrinsic rhythm
to DDDR-paced or possibly atrial-paced rhythms.
Biventricular pacing
Right ventricular pacing, intrinsic to DDDR/ICDs, may be
detrimental to patients with significant ventricular dysfunction.
The current multicenter trials evaluating biventricular pacing in
both pacemaker and ICD patients suggest that prolonged
ventricular electrical activation time, particularly due to
complete left bundle branch block, causes an inefficient left
ventricular contraction pattern. This may have a negative
impact on LV function and produce more significant
congestive heart failure symptoms. This pattern is precisely
what occurs with right ventricular pacing. Thus the use of a
DDDR/ICD with a right ventricular lead may reduce ventricular
function and produce more congestive heart failure.
Comorbidities
ICD patients exist in a complicated cardiovascular milieu. In
addition to the VT/VF required for entry into the AVID trial,
patients had a mean LVEF of 32%. Forty six per cent of
patients had a history of congestive heart failure, and 33%
had a history of atrial fibrillation [4]. Most interestingly, if
patients were admitted to the hospital for a diagnosis of
congestive heart failure during the trial, their mortality rate
over the subsequent two years was 50%, and this was no
different in both the drug therapy and ICD arms of the trial [A
Hallstrom, personal communication of unpublished
observations from the AVID database]. By preventing death
from VF in ICD patients, atrial fibrillation, bradycardia, and
congestive heart failure will have a proportionally greater
negative influence on mortality. Thus, if DDDR/ICDs are to
reduce cardiovascular mortality or improve symptoms then
they must significantly impact these comorbid conditions.
It is logical to expect DDDR/ICDs to impact on these
conditions through several mechanisms. First, there are
increasing data that support the use of atrial pacing to
prevent atrial fibrillation. The clearest result of the Danish andc
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Canadian experience was that atrial pacing reduced the
incidence of atrial fibrillation [1,3]. Second, atrial and
ventricular tachyarrhythmias are often treated with negative
chronotropic medications such as sotalol and amiodarone,
and the lack of dual chamber pacing limits the ability to use
these medications. Finally, the major comorbidity, responsible
for most of the nonarrhythmic mortality in ICD patients, is
congestive heart failure. The use of beta-blockers for patients
with congestive heart failure has been shown to improve
survival. When a VVI/ICD is implanted the use of beta-
blockers is frequently limited by the potential for VVI pacing
and significant bradycardia.
Endpoints
What is the incremental benefit of DDDR/ICDs over single
chamber devices? There are three significant endpoints that
should be considered. Do these devices improve prognosis,
improve quality of life, or reduce the cost of treating these
patients? Prognosis could be improved by reducing
arrhythmic mortality, heart failure mortality, and stroke
mortality. Quality of life could be improved by reducing the
number of appropriate and inappropriate ICD shocks,
reducing hospitalization due to ICD shocks or heart failure,
and improving the tolerance of antiarrhythmic and heart
failure medications, which result in improved heart failure
status. Finally, it is possible that dual chamber devices will
reduce costs to the medical system by reducing inpatient
and outpatient visits, reduce reoperations for upgrades from
a single chamber ICD, and reduce the need to use other
diagnostic tests for rhythm diagnosis, since atrial sensing
improves the ability to diagnose an arrhythmia. The DAVID
trial is designed to answer these questions.
Conclusion
The major move towards biventricular pacing will come, when
biventricular pacing and defibrillator therapy is combined with
all of the features of conventional DDDR/ICDs. It is
conceivable that, in certain situations, it will be better to
place a VVI/ICD instead of a DDDR/ICD, or a DDDR/ICD
instead of a biventricular pacing DDDR/ICD. Just as the
impact of left ventricular stimulation is not yet established,
neither has the incremental value of DDDR/ICDs over
VVI/ICDs been determined. In the end, it is crucial that we
understand the implications of these changes in technology.
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